JWJiachen Wu

Jiachen Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiachen Wu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure S1-6 from PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis

    by Shuang Tang, Qian Zhou, Johann S. Bergholz, Tao Jiang, Weihua Wang, Renlei Ji, Wendi Huang, Jiachen Wu, Yutong Li, Xiaochun Wan, et al.

    Figure S1. Bio-ID screening reveals PI3Kβ, but not PI3Kα, as a selective interactor of EPHA2 in PTEN-null cancer cells. Figure S2. PTEN acts as a protein tyrosine phosphatase regulating PI3Kβ- EPHA2 interaction through dephosphorylation of tyrosine-962 (Y962) on PI3Kβ and impact tumorigenesis. Figure S3. Generation of a new antibody to detect phospho-PI3KβY962 levels. Figure S4. PI3Kβ and EPHA2 upregulate pERK/c-MYC and pAKT signaling in PTEN null cancer. Figure S5. Compound library screening identifies dasatinib as an inhibitor of PI3KβY962 phosphorylation that effectively inhibits PTEN-null tumor growth. Figure S6. Phosphorylation of PI3Kβ is a druggable target to treat PTEN-null tumors in vivo.

  • Open Access

    Supplementary Table 1 from PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis

    by Shuang Tang, Qian Zhou, Johann S. Bergholz, Tao Jiang, Weihua Wang, Renlei Ji, Wendi Huang, Jiachen Wu, Yutong Li, Xiaochun Wan, et al.

  • Open Access

    PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis

    by Shuang Tang, Qian Zhou, Johann S. Bergholz, Tao Jiang, Weihua Wang, Renlei Ji, Wendi Huang, Jiachen Wu, Yutong Li, Xiaochun Wan, et al.

    Loss of the tumor-suppressor PTEN drives cancer progression and therapeutic resistance, yet no targeted therapies exist for PTEN-deficient tumors. In this study, we identify a critical druggable mechanism in which PTEN loss induces PI3Kβ phosphorylation for tumorigenesis. Using the BioID interactome, we uncovered a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells, driven by p-PI3KβY962. PTEN functions as a tyrosine phosphatase that normally dephosphorylates p-PI3KβY962. In PTEN-deficient contexts, enhanced p-PI3KβY962 forms a complex with EPHA2 and SRC, in which both kinases contribute to PI3Kβ phosphorylation, activating oncogenic pERK/c-MYC and pAKT pathways. We developed a selective p-PI3KβY962 antibody detecting p-PI3KβY962 in PTEN-deficient tumors across preclinical models and clinical tumor specimens. Disrupting p-PI3KβY962 suppressed tumor growth in multiple PTEN-null models. Dasatinib, an FDA-approved SRC/EPHA2 inhibitor, effectively reduced p-PI3KβY962 and inhibited tumor progression in PTEN-null but not PTEN wild-type tumors. These findings establish p-PI3KβY962 as a druggable target and biomarker for developing targeted therapy in PTEN-deficient cancers beyond conventional PI3K kinase inhibition. Significance: We revealed a critical new mechanism that PTEN loss induces PI3Kβ phosphorylation and EPHA2/SRC/p-PI3KβY962 complex signaling to drive tumorigenesis. This work directs pharmaceutical development of p-PI3KβY962 inhibitors and biomarker-driven clinical trials repurposing dasatinib for PTEN-deficient solid tumor treatment, with potential to significantly improve outcomes of broad patients with PTEN-deficient tumors.